简介:Toevaluatetheeffectby“standard/chemotherapywithnavelbine(NVB)pluscisplatin(PDD)inthetreatmentofnonsmallcelllungcancer(NSCLC).”MethodsTherewere40NSCLCpatientsinthisstudy.38weremaleand2female.Themedianageofthepatientswas52yearsold.Squamouscarcinomawasthemostconmontypeofmalignancy(36cases).SixteenpatientswereinthestageⅢaand20patientsinstageⅢb-ⅣTwentypatientshadnopriorchemotherapyand20receivedpreviouschemotherapy.ResultsCompleteresponsewasobservedin4patientsandpartialresponsein15patients.Theoverallresponseratewas47.5%.Theresponserateoftheprimarychemothera-pywas60%.Thesecondarychemotherapywas35%.ThemaintoxityofNVBwasneutropeniawhichwasseeninalltreatedcases(80.5%inGradeⅡandⅢ)Thelocalvenoustoxitywasobservedin35%ofthepatients.ConclusionTheso-calledstandardchemotherapywithNVBplusPDDinthetreatmentofNSCLCmayobtainahigherresponserateandlowertoxity.Itiseffectiveespeciallyforthepatientsofinanearlierstage.
简介:摘要目的探讨他汀类降血脂药物辛伐他汀和贝特类降血脂药物非诺贝特的降脂疗效与安全性。方法将符合条件的192例原发性高脂血征患者按2︰1的比例随机分为两组,其中辛伐他汀128例,非诺贝特组64例。辛组口服辛伐他汀20mg每日一次,晚餐后顿服。非组非诺贝特0.2每晚一次,晚餐时服。共观察12周,并于治疗前、治疗4W、8W、12W均监测血脂及肝、肾功能。肌酸、磷酸、激酶等生化指标。结果辛伐他汀降低总胆固醇(TC)血浆低密度脂蛋白胆固醇(LDL-C)的平均百分比明显优于非诺贝特;而非诺贝特在降低血浆甘油三脂(TG)方面较为有效,差异具有显著性,有统计学意义(P<0.01),在升高高密度脂蛋白的胆固醇(HDL-C)方面无显著性(P>0.05)两者不良反应均较少。结论辛伐他汀和非诺贝特在降血脂治疗方面都是有效和安全的。